Hims & Hers Launches Peptides+ to Expand Personalized Health Care

Zacks
Open on Zacks
Hims & Hers Launches Peptides+ to Expand Personalized Health Care

Hims & Hers Health, Inc. HIMS recently launched Peptides+, a new specialty offering clinically guided peptide therapies and personalized treatment plans. The service provides eligible customers access to up to five treatments at launch, including Sermorelin, NAD+, Glutathione, Vitamin B12 and L-Carnitine. The initiative expands the company's personalized health offerings, targeting customers seeking proactive approaches to health, wellness and age-related changes.

Per management, the Peptides+ is designed to offer men personalized, clinically guided treatment plans tailored to their health goals, with support from licensed providers and greater transparency about the therapies used. For women, the Peptides+ aims to provide a more comprehensive, individualized approach that considers their health history, changing needs and personal goals, supported by evidence-based decisions, medical guidance and ongoing care.

HIMS Stock Trend Following the News

Shares of HIMS have lost 6% since the announcement on Wednesday. Year to date, the stock plunged 50.7%, underperforming the industry’s 9% growth and the S&P 500’s 5.9% gain.

The launch could strengthen Hims & Hers' growth prospects by expanding its addressable market beyond traditional telehealth and prescription services into personalized longevity and specialty wellness care. The addition of peptide-based treatments may help the company attract new customer segments while creating opportunities to increase engagement among existing subscribers. Integrating these offerings with lab testing, provider consultations and ongoing care could also support cross-selling opportunities, improve customer retention and deepen the company's position in the evolving personalized healthcare market.

HIMS currently has a market capitalization of $4 billion.

Zacks Investment Research
Image Source: Zacks Investment Research

More on Peptides+

Peptides+ follows a provider-led model in which customers undergo a comprehensive assessment of their health history and goals before receiving a personalized treatment plan, if deemed appropriate. Treatments are compounded in the United States and dispensed through licensed U.S. pharmacies regulated by state boards of pharmacy. Dedicated care teams conduct regular follow-ups and can adjust treatment plans based on customers' changing needs.

The five treatments available at launch address different aspects of cellular function and overall health. Sermorelin supports the body's growth hormone signaling, while NAD+ plays a role in cellular energy production and DNA repair. Glutathione supports antioxidant defenses, Vitamin B12 contributes to energy production and nervous system health, and L-Carnitine supports cellular energy metabolism.

Peptides+ is available through Care+, which combines treatment with additional monitoring and support services. Customers receive twice-yearly laboratory testing, unlimited access to a dedicated Care Team and the ability to message providers trained in peptide therapies around the clock.

The launch expands Hims & Hers' at-home testing capabilities. The Hims Men's panel and Hers Women's panel each assess 22 biomarkers, covering areas such as hormones, vitamins and cardiovascular health. The women's panel marks the first time Hers is offering at-home blood collection for women. Eligible Care+ customers may also consult providers about testosterone treatment based on their laboratory results.

Hims & Hers plans to expand the Peptides+ portfolio with additional therapies, including BPC-157 and TB-500, subject to applicable regulatory standards. The expansion could further broaden the company's specialty healthcare platform and strengthen its focus on personalized, ongoing care.

Industry Prospects Favoring the Market

According to Grand View Research, the global peptide therapeutics market is estimated to reach $164 billion in 2026 and is projected to grow at a CAGR of 8.7% through 2033.

Factors such as rising demand for targeted therapies, increasing prevalence of metabolic disorders, diabetes and obesity, growing interest in personalized healthcare, advancements in peptide synthesis and drug delivery technologies and expanding applications of peptide-based treatments are driving market growth.

Other News

Hims & Hers Health recently partnered with Eli Lilly and Company to expand patient access to Lilly’s FDA-approved obesity treatments, Zepbound and Foundayo, through its digital health platform. Eligible patients with prescriptions from licensed providers can access the medicines at self-pay prices starting at $149 per month for Foundayo and $299 for Zepbound, with consultations, prescriptions and home delivery available through the platform.

Hims & Hers Health, Inc. Price

Hims & Hers Health, Inc. Price

Hims & Hers Health, Inc. price | Hims & Hers Health, Inc. Quote

HIMS’ Zacks Rank & Key Picks

Currently, HIMS carries a Zacks Rank #4 (Sell).

Some top-ranked stocks from the broader medical space are Glaukos GKOS, Intuitive Surgical ISRG and West Pharmaceutical Services WST.

Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.

Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.

Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.

West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.

WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Hims & Hers Health, Inc. (HIMS): Free Stock Analysis Report
 
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
 
West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report
 
Glaukos Corporation (GKOS): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research